Abstract | INTRODUCTION: MATERIALS AND METHODS: We conducted a retrospective study of patients receiving aPCC for DOAC-associated bleeding or for pre-operative optimization of hemostasis prior to urgent surgery. The primary efficacy outcome was hemostatic efficacy, the primary safety outcome was the 30-day thromboembolic complication rate. RESULTS: Eighty-two patients were included in the analysis; 14 patients on dabigatran, 39 patients on rivaroxaban and 29 patients on apixaban. Fifty-four patients received aPCC for major bleeding and 28 patients prior to urgent surgery. Mean aPCC dosing was 2974 IU (SD ± 857 IU). Hemostasis was deemed effective by ISTH criteria in 50% of cases and "Good" or "Moderate" by Sarode criteria in 45.2% and 14.3% of cases, respectively. Surgical hemostasis was rated as "Normal" in 84% of cases pre-operative administration. Median pre-aPCC INR was 1.6 (IQR 0.5) and median post-aPCC INR was 1.2 (IQR 0.2) (p < 0.00001). Median pre-aPCC aPTT was 36 s (IQR 12.8), median post-aPCC aPTT was 29 s (IQR 9.8) (p = 0.0001). The 30-day thromboembolic event rate was 6.1%. CONCLUSION: Further study is needed to characterize the hemostatic effects and thromboembolic risk of aPCC among patients with DOAC-associated bleeding or for attempted normalization of hemostasis prior to urgent surgery.
|
Authors | Joseph R Shaw, Marc Carrier, Dar Dowlatshahi, Santanu Chakraborty, Melanie Tokessy, Hakan Buyukdere, Lana A Castellucci |
Journal | Thrombosis research
(Thromb Res)
Vol. 195
Pg. 21-28
(11 2020)
ISSN: 1879-2472 [Electronic] United States |
PMID | 32645667
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020. Published by Elsevier Ltd. |
Chemical References |
- Anticoagulants
- Blood Coagulation Factors
- Hemostatics
- prothrombin complex concentrates
- Rivaroxaban
- Dabigatran
|
Topics |
- Administration, Oral
- Anticoagulants
(adverse effects)
- Blood Coagulation Factors
- Dabigatran
- Hemorrhage
(chemically induced, drug therapy)
- Hemostasis
- Hemostatics
- Humans
- Retrospective Studies
- Rivaroxaban
|